Research News

A recent mouse model based study suggests that blocking TGF-β may improve osteoporosis treatment by helping quiescent osteoblasts in inactive bone surfaces return to an active state. Using spatial transcriptomics, single-cell analysis, and functional experiments, researchers identified TGF-β signaling as a regulator of osteoblast activation. In a bone-loss mouse model, dual inhibition of TGF-β and sclerostin increased bone mass more effectively than sclerostin inhibition alone, highlighting a promising combination strategy.

A surprising breakthrough in anti-aging research raises hopes of delaying muscle aging and weakness by harnessing the potential of a garlic-derived compound, S-1-propenyl-L-cysteine (S1PC). Researchers identify a key role for S1PC in orchestrating a key inter-organ communication between fat tissue and the hypothalamus in the brain, thus supporting muscle function in aged mice. Elements of this signaling mechanism were also observed in humans, highlighting the potential of S1PC-based anti-aging interventions.

Short QT syndrome is a genetic disease that leads to sudden cardiac death at a young age. Mutations in the SLC4A3 gene, which regulates bicarbonate-chloride exchange, were recently described as a potential cause. An international research team including a group from Ruhr University Bochum, Germany, investigated this possibility. The researchers discovered how different variants of the gene affect heart muscle cells: Specifically, the pH level increased and the flow of ion channels was altered. This insight could aid in providing better personal care for persons affected by the disease.

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) - which is one of the leading reasons why chemotherapy fails in patients. This research addresses that problem with a fundamentally new strategy: instead of simply increasing drug doses or switching drugs, researchers engineered nanoparticles that first disable the cancer cell's drug-expulsion mechanism, and only then release the anticancer drug.

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study* presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery (#ASMBS2026).

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

Johnson & Johnson announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026.